TOLREMO therapeutics Funding: $39M Raised, Series A (2023)
TOLREMO therapeutics is based in Basel, Switzerland. It has raised $39M in total funding. Latest round: Series A.
TOLREMO therapeutics funding overview
TOLREMO therapeutics is based in Basel, Switzerland. TOLREMO therapeutics has raised $39M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in September 2023. The round record for TOLREMO therapeutics runs through 2023; nothing later has been disclosed. Investors on record include BioMedPartners AG, Pierre Fabre Invest, Redalpine, Altos Venture, Zürcher Kantonalbank. 5 distinct backers are named across the disclosed rounds.
TOLREMO therapeutics at a glance
Total raised
$39M
Latest round
Series A
Latest round date
September 2023
Headquarters
Basel, Switzerland
Notable investors
BioMedPartners AG, Pierre Fabre Invest, Redalpine, Altos Venture, Zürcher Kantonalbank
Frequently asked about TOLREMO therapeutics funding
How much has TOLREMO therapeutics raised?
TOLREMO therapeutics has raised $39M in total disclosed funding across the rounds on record.
Who has invested in TOLREMO therapeutics?
BioMedPartners AG, Pierre Fabre Invest, Redalpine, Altos Venture, Zürcher Kantonalbank are named among the investors backing TOLREMO therapeutics.
What was the latest TOLREMO therapeutics funding round?
The most recent disclosed round is a Series A, announced in September 2023.
Where is TOLREMO therapeutics based?
TOLREMO therapeutics is based in Basel, Switzerland.
When did TOLREMO therapeutics last raise?
The last disclosed TOLREMO therapeutics round closed in September 2023 at Series A.
Totals shown for TOLREMO therapeutics aggregate every disclosed round on file. To see how that compares, browse the companies in Basel and the investors behind them below.
